Search

Your search keyword '"Ruiz Alvarez, M"' showing total 11 results
Start Over Author "Ruiz Alvarez, M" Publication Year Range Last 50 years
11 results on '"Ruiz Alvarez, M"'

7. Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART

Author

Ensoli, B., Bellino, S., Tripiciano, A., Longo, O., Francavilla, V., Marcotullio, S., Cafaro, A., Picconi, O., Paniccia, G., Scoglio, A., Arancio, A., Ariola, C., Ruiz Alvarez, M. J., Campagna, M., Scaramuzzi, D., Iori, C., Esposito, R., Mussini, C., Ghinelli, F., Sighinolfi, L., Palamara, G., Latini, A., Angarano, G., Ladisa, N., Soscia, F., Mercurio, V. S., Lazzarin, A., Tambussi, G., Visintini, R., Mazzotta, F., Di Pietro, M., Galli, M., Rusconi, S., Carosi, G., Torti, C., Di Perri, G., Bonora, S., Ensoli, F., Garaci, E., and Segala, D.

Subjects
CD4-Positive T-Lymphocytes, Male, T-Lymphocytes, HIV Infections, CD38, CD8-Positive T-Lymphocytes, Lymphocyte Activation, T-Lymphocytes, Regulatory, Antiretroviral Therapy, Highly Active, vaccine, Cytotoxic T cell, Homeostasis, Killer Cells, Prospective Studies, tat, Virology/Vaccines, AIDS Vaccines, B-Lymphocytes, Multidisciplinary, HIV, AIDS, Nausea, Infectious Diseases/HIV Infection and AIDS, Middle Aged, Settore MED/07 - Microbiologia e Microbiologia Clinica, Combined Modality Therapy, Regulatory, Killer Cells, Natural, medicine.anatomical_structure, Treatment Outcome, Virology/Immunodeficiency Viruses, Natural, Medicine, tat Gene Products, Human Immunodeficiency Virus, Female, Adult, Aged, Asthenia, HIV-1, Humans, Immunization, Cell activation, tat Gene Products, Human Immunodeficiency Virus, Research Article, Science, T cell, Antiretroviral Therapy, Pathology/Immunology, Biology, NO, Immune system, Antigen, Immunology/Immunity to Infections, medicine, Highly Active, Virology, Immunology, CD8
Abstract

UnlabelledAlthough HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and to cell activation. Of note, in CD4(+) T cells and monocyte-macrophages of virologically-suppressed individuals, there is continued expression of multi-spliced transcripts encoding HIV regulatory proteins. Among them, Tat is essential for virus gene expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune responses, and modified the pattern of CD4(+) and CD8(+) cellular activation (CD38 and HLA-DR) together with reduction of biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive increment of CD4(+) T cells and B cells with reduction of CD8(+) T cells and NK cells, which were independent from the type of antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory CD4(+) and CD8(+) T cells were accompanied by increases of CD4(+) and CD8(+) T cell responses against Env and recall antigens. Of note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART efficacy and to restore immune homeostasis.Trial registrationClinicalTrials.gov NCT00751595.

Published
2010

10. [Differences in the synthesis pattern of vasoactive factors in gestational hypertension and preeclampsia].

Author

Ruiz Alvarez MJ, Bouarich H, Oñate S, Rodríguez Puyol D, and Arribas I

Subjects
Adult, Case-Control Studies, Catecholamines urine, Cyclic GMP blood, Endothelins blood, Female, Humans, Nitrites blood, Pregnancy, Prospective Studies, Renal Insufficiency etiology, Hypertension, Pregnancy-Induced physiopathology, Pre-Eclampsia physiopathology
Abstract

Background and Objective: The gestational hypertension -HG- and preeclampsia -P- are hypertensive diseases whose pathogenic mechanism has not been determined yet. The aim of this work is to define some patterns of vasoactive factors release that allow to explain the origin of the differences between both entities., Design: Prospective case-control study., Material and Methods: Two groups of target patients were consecutively selected, GH (n=21) and P patients (n=21). Every patient was matched with a pregnant of similar age and week of pregnancy. Two control groups were obtained, one respect to the GH and another one respect to the P group. A biochemistry, blood cell count, coagulation and quantification of vasoactive factors endothelin, nitrites and GMPc were performed in every woman. Results of GH and P groups were compared with their respective control group with the paired Student's t Test., Results: Both systolic and diastolic arterial pressures were higher in hypertensive pregnants (GH and P) than in their respective controls. Moreover, blood endothelin and GMPc were higher in GH and P. GH pregnants showed decreased norepinephrine and increased epinephrine urinary excretion , as well as an increased plasma nitrites concentration than control group. P patients did not show statistically significant differences in catecholamines urinary excretion nor in plasma nitrites concentration respect their control group., Conclusion: There are relevant differences in the synthesis patterns of vasoactive factors between gestational hypertension and preeclampsia. These differences could account for a decreased tissue perfusion in preeclampsia and could also contribute to the genesis of the renal dysfunction of this entity.

Published
2007

11. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.

Author

Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, Collacchi B, Ruiz-Alvarez M, Giannetto C, Caputo A, Tomasoni L, Castelli F, Sciandra M, Sinicco A, Ensoli F, Buttò S, and Ensoli B

Subjects
Acquired Immunodeficiency Syndrome immunology, Adolescent, Adult, Aged, Antibody Specificity, Cohort Studies, Disease Progression, Disease Susceptibility, Female, Humans, Male, Middle Aged, Survival Analysis, Time Factors, tat Gene Products, Human Immunodeficiency Virus, Gene Products, tat immunology, HIV Antibodies immunology, HIV Long-Term Survivors, HIV Seropositivity immunology
Abstract

The human immunodeficiency virus (HIV) type 1 Tat protein plays a key role in the life cycle of the virus and in pathogenesis and is highly conserved among HIV subtypes. On the basis of this and of safety, immunogenicity, and efficacy findings in monkeys, Tat is being tested as a vaccine in phase 1 trials. Here, we evaluated the incidence and risk of progression to advanced HIV disease by anti-Tat serostatus in a cohort of 252 HIV-1 seroconverters. The risk of progression was lower in the anti-Tat-positive subjects than in the anti-Tat-negative subjects. Progression was faster in the persistently anti-Tat-negative subjects than in the transiently anti-Tat-positive subjects, and no progression was observed in the persistently anti-Tat-positive subjects.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results